FDA Approves XCOPRI® (cenobamate tablets), an Anti-Epileptic Drug (AED) from SK Biopharmaceuticals, Co., Ltd., and ...
(World News Science)

PANGYO, South Korea and PARAMUS, N.J., Nov. 21, 2019 /PRNewswire/ -- , an innovative global pharmaceutical company focused on developing and bringing treatments to market for central nervous system (CNS) disorders, and its U.S. subsidiary announced today that the U.S. Food and Drug Administration (FDA) approved XCOPRI® (cenobamate tablets) as a treatment for partial-onset seizures in adults. Experience the interactive Multichannel News Release here: `The approval of XCOPRI will provide clinicians with an effective medication for our patients who are continuing to have focal (partial-onset) seizures,` said Michael Sperling, MD, Professor of Neurology and Director of the Jefferson...